Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2020 e » 2020 _ (Expand Search), 2020 p (Expand Search), 2020 n (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2020 e » 2020 _ (Expand Search), 2020 p (Expand Search), 2020 n (Expand Search)
-
581
Algorithm operation steps.
Published 2025“…Experimental results demonstrate that SCI-YOLO11 achieves a 3.2% improvement over baseline models in terms of MAP@0.5 metric; precision and recall rates increase by 2.6% and 3.7%, respectively. …”
-
582
-
583
-
584
-
585
-
586
-
587
-
588
-
589
Tunicamycin produces a concentration- and time-dependent decrease in cell viability in SH-SY5Y cells concomitant with caspase-3 activation.
Published 2013“…<p>(A) Treatment of SH-SY5Y cells with tunicamycin (0.1–5µM) for 24 h caused a progressive decrease in cell viability as measured by Calcein AM cleavage assay. …”
-
590
-
591
-
592
-
593
-
594
-
595
The novel <i>carboxylesterase 1</i> variant c.662A>G may decrease the bioactivation of oseltamivir in humans
Published 2017“…A novel <i>CES1</i> c.662A>G single nucleotide polymorphism (SNP) was predicted to decrease CES1 enzymatic activity in an <i>in silico</i> analysis. …”
-
596
-
597
-
598
-
599
-
600
(R)-albuterol decreases cytokine mRNA levels in activated T cells
Published 2011“…</p><p></p> (R)-albuterol, (S)-albuterol or racemic albuterol (R + S) at a dose (10M) were added to T (EL-4) cells pre-activated with mitogens Concanavalin A (Con A, 5 μg/ml) and phorbol myristate acetate (PMA, 100 ng/ml) (CP). …”